Aquestive Therapeutics, Inc.
NASDAQ: AQST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Daniel Barber
- Employees
- 142
- Headquarters
- Warren, United States
- IPO year
- 2018
- Market cap
- $495.5M
- Website
- https://www.aquestive.com
Loading AQST…
Loading profile data…Frequently asked questions about AQST
What does Aquestive Therapeutics, Inc. (AQST) do?
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with...
Where does AQST trade?
Aquestive Therapeutics, Inc. (AQST) trades on the NASDAQ Global Market.
What sector is AQST in?
Aquestive Therapeutics, Inc. (AQST) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Aquestive Therapeutics, Inc.?
Daniel Barber is the chief executive officer of Aquestive Therapeutics, Inc. (AQST).
Where is Aquestive Therapeutics, Inc. headquartered?
Aquestive Therapeutics, Inc. is headquartered in United States.
Does AQST pay a dividend?
Aquestive Therapeutics, Inc. (AQST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AQST go public?
Aquestive Therapeutics, Inc. (AQST) completed its initial public offering in 2018.